Genzyme/Sanofi’s oral MS drug Aubagio beats placebo in PhIII

Genzyme continues to build the large late-stage data package for teriflunomide, an oral multiple sclerosis drug that the company and its owner, Sanofi ($SNY), are developing to compete in the blockbus…
Read the full story: News